| Robert Wh Mason, MD | |
|
28 White Bridge Pike, Ste. 208, Nashville, TN 37205-1467 | |
| (615) 327-2001 | |
| (615) 234-2015 |
| Full Name | Robert Wh Mason |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 28 Years |
| Location | 28 White Bridge Pike, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124077359 | NPI | - | NPPES |
| 2443399 | Medicaid | LA |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeast Eye Specialists Pllc | 6800708504 | 31 |
News Archive
A study led by researchers at RCSI's Department of Chemistry has the potential to help surgeons more accurately remove tumors and detect cancer in lymph nodes during surgery.
With over 3.25 million people infected, healthcare systems of even the most developed nations are overwhelmed. Cancer patients and survivors, for example, are particularly vulnerable during this epidemic and not only because of their increased vulnerable immunocompromised state, which makes them prone to the infection. They are also at risk of missing out on essential cancer care due to the unavailability of resources.
Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Numerous studies show that non-steroidal anti-inflammatory drugs reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation.
› Verified 8 days ago
| Entity Name | Southeast Eye Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518961176 PECOS PAC ID: 6800708504 Enrollment ID: O20031103000021 |
News Archive
A study led by researchers at RCSI's Department of Chemistry has the potential to help surgeons more accurately remove tumors and detect cancer in lymph nodes during surgery.
With over 3.25 million people infected, healthcare systems of even the most developed nations are overwhelmed. Cancer patients and survivors, for example, are particularly vulnerable during this epidemic and not only because of their increased vulnerable immunocompromised state, which makes them prone to the infection. They are also at risk of missing out on essential cancer care due to the unavailability of resources.
Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Numerous studies show that non-steroidal anti-inflammatory drugs reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Wh Mason, MD 341 Cool Springs Blvd., Ste. 400, Franklin, TN 37067 Ph: (423) 508-7337 | Robert Wh Mason, MD 28 White Bridge Pike, Ste. 208, Nashville, TN 37205-1467 Ph: (615) 327-2001 |
News Archive
A study led by researchers at RCSI's Department of Chemistry has the potential to help surgeons more accurately remove tumors and detect cancer in lymph nodes during surgery.
With over 3.25 million people infected, healthcare systems of even the most developed nations are overwhelmed. Cancer patients and survivors, for example, are particularly vulnerable during this epidemic and not only because of their increased vulnerable immunocompromised state, which makes them prone to the infection. They are also at risk of missing out on essential cancer care due to the unavailability of resources.
Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves - as well as the largest, most scientifically rigorous study to examine the question - reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.
Numerous studies show that non-steroidal anti-inflammatory drugs reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation.
› Verified 8 days ago
Dr. Peter L Sonkin, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 23rd Ave N, Suite 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 | |
Dr. Edward Chaum, MD PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-936-3000 | |
Dr. Mark R Melson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4306 Harding Pike, Suite 106, Nashville, TN 37205 Phone: 615-297-5798 Fax: 615-383-6646 | |
Dr. Everton L. Arrindell, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 - 23rd Avenue North, Suite 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 | |
Dr. Christine Shieh, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Lucas Lee Groves, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Brigid K Marshall, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 345 23rd Ave N Ste 350, Nashville, TN 37203 Phone: 615-983-6000 Fax: 615-983-6010 |